Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Full Year 2022 and Fourth Quarter (Q4) 2022
Issuance Date: February 1, 2023
GSK reported a landmark year in 2022, driven by strong commercial execution in Specialty Medicines and Vaccines. The company completed the demerger of its Consumer Healthcare business (Haleon) on July 18, 2022, which is now presented as discontinued operations. The results reflect a strategic shift toward a biopharma company focused on infectious diseases and the science of the immune system.
Key Financial Metrics
| Metric | Full Year 2022 | Q4 2022 | Notes |
|---|---|---|---|
| Turnover | £29.3 billion | £7.4 billion | Full Year: +19% AER, +13% CER. Q4: +4% AER, -3% CER. |
| Adjusted Operating Profit | £8.2 billion | £1.6 billion | Full Year: +26% AER, +14% CER. Q4: +21% AER, +5% CER. |
| Adjusted Operating Margin | 27.8% | 21.6% | Full Year margin up 1.5pp AER vs 2021. |
| Adjusted EPS | 139.7p | 25.8p | Full Year: +27% AER, +15% CER. Q4: +10% AER, -6% CER. |
| Total EPS | 371.4p | 37.1p | Includes £10.1 billion gain from Consumer Healthcare demerger. |
| Cash from Operations (Continuing) | £7.9 billion | £2.1 billion | Full Year: +10% vs 2021. |
| Free Cash Flow (Continuing) | £3.3 billion | £0.9 billion | Full Year: +1% vs 2021. |
| Net Debt | £17.2 billion | £17.2 billion | Reduced by £2.6 billion in 2022. |
Material Changes vs. Prior Period
- Revenue Growth: Full-year sales grew 13% at constant exchange rates (CER), excluding COVID-19 solutions. Specialty Medicines grew 29% CER, driven by HIV (+12% CER) and Oncology (+17% CER). Vaccines grew 11% CER, led by Shingrix (+60% CER). General Medicines grew 1% CER.
- COVID-19 Impact: Sales of COVID-19 solutions (primarily Xevudy) were £2.3 billion in 2022. Q4 2022 results were impacted by a high comparator in Q4 2021 due to strong Xevudy sales, resulting in a 3% CER decline in total turnover for the quarter.
- Discontinued Operations: The demerger of Consumer Healthcare generated a total gain of £10.1 billion recognized in 2022, significantly boosting Total EPS to 371.4p. This is excluded from Adjusted results.
- Profitability: Adjusted operating profit grew 14% CER, supported by operating leverage and mix benefits, partially offset by lower-margin COVID-19 sales and increased launch investments.
Guidance, Outlook, and Risks
2023 Guidance (Constant Exchange Rates)
Guidance excludes any contribution from COVID-19 solutions.
- Turnover: Expected to increase between 6% and 8%.
- Adjusted Operating Profit: Expected to increase between 10% and 12%.
- Adjusted EPS: Expected to increase between 12% and 15%.
Management Commentary
CEO Emma Walmsley highlighted 2022 as a "landmark year" delivering a step change in performance. The company enters 2023 with momentum from record Shingrix sales and a robust pipeline. Dividend policy remains unchanged, with an expected total dividend of 56.5p per share for 2023.
Risks and Contingencies
- Legal Proceedings:
- Zantac: A federal court granted summary judgment in favor of GSK in the Multi-District Litigation (MDL), dismissing ~2,200 cases. However, state-level litigation continues, with a bellwether trial expected in February 2023.
- Zofran: The US Court of Appeals affirmed a summary judgment in favor of GSK. Limited state and Canadian cases remain.
- Pipeline Risks: The pivotal Phase III trials for gepotidacin (antibiotic) were stopped early for efficacy (positive outcome), but other trials like Blenrep (DREAMM-3) did not meet primary endpoints, leading to a US market withdrawal request.
- Macro Environment: Uncertain economic conditions and exchange rate fluctuations remain risks. The company expects variability in quarterly performance.
Investor Verification Checklist
- COVID-19 Sustainability: Verify the trajectory of Xevudy sales and the impact of new variants on demand, as 2023 guidance explicitly excludes these solutions.
- Shingrix Growth: Confirm the sustainability of the 60% CER growth in Shingrix sales and potential market saturation or reimbursement changes.
- Legal Exposure: Monitor the outcome of the California Zantac bellwether trial scheduled for February 2023 and any potential indemnification claims.
- Pipeline Milestones: Track regulatory decisions for the RSV older adult vaccine (expected 2023) and the status of the Blenrep program in earlier lines of therapy.
- Dividend Payout: Verify the ability to maintain the 56.5p dividend per share for 2023 given the 40-60% payout ratio policy and capital allocation for R&D and M&A.